In vivo imaging platforms
In vivo imaging platforms in the Paris Region. Along with other research agencies, the Life sciences division is complementing the technical resources located in the Paris area (and including the imaging facilities of the Service Hospitalier Frédéric Joliot in Orsay) with two new imaging platforms, thus taking an active part in the formation of an European centre of excellence.
NON-INVASIVE METHODS AND FUNCTIONAL EXPLORATION
||The CEA's Frederic Joliot Hospital Service (SHFJ) is still today the only research centre in Europe that groups most of the current non-invasive methods of human functional exploration (single photon emission tomography, positron emission tomography, nuclear magnetic resonance imaging and spectroscopy, etc.) while at the same time running both pure research departments and a clinical unit for nuclear medicine.|
A CENTRE FOR IMAGING BY HIGH-FIELD NUCLEAR MAGNETIC RESONANCE
Understrand the brain by the image
The goal of NeuroSpin is to push the current limits of brain imaging, from the mouse to man, as far as possible with very high magnetic field Nuclear Magnetic Resonance (NMR). NMR imaging (MRI) can be used to observe deep organs totally non-invasively. The more intense the magnetic field, the greater the sensitivity, allowing more details to be seen. Benefiting from CEA know-how in the conception of magnets and NMR, this technical platform will be equipped with unrivalled NMR imaging tools.
A PRECLINICAL IMAGING PLATFORM FOR GENE AND CELL THERAPIES
Improve understanding and treatment of neurodegenerative, hepatic and cardiac diseases.
||CEA and Inserm propose a pre-clincal imaging platform, to design, implement and validate innovative therapies for the treatment of neurodegenerative, hepatic and cardiac diseases, and AIDS. The pre-clinical imaging platform's objective is to bring together the various current techniques and skills in molecular biology, cell biology, electrophysiology and behavioural science around radio-isotope and anatomic functional imaging techniques, in order to design, develop and validate new approaches to cell therapy, gene therapy and intervention surgery|